Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11032344 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL4473488 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL11130621 | 0.95 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL11130618 | 0.95 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL20611377 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| Tetradecane SCHEMBL27504192 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL5233459 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL17069045 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL5233467 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 | |
| SCHEMBL17401020 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2APOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456254-B | Synthesis method of C-type natriuretic peptide analogue Vosoritide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-114456254-A | Synthesis method of C-type natriuretic peptide analogue Vosolitide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| WO-2008038143-A2 | NOVEL SOLID FORMS OF RIMONABANT AND SYNTHETIC PROCESSES FOR THEIR PREPARATION | MEDICHEM, S.A. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-114456254-B | Synthesis method of C-type natriuretic peptide analogue Vosoritide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114456254-B | Synthesis method of C-type natriuretic peptide analogue Vosoritide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230018246-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2023-01-19 | — | — | US | disclosed |
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-06-21 | — | — | US | disclosed |
| CN-114456254-A | Synthesis method of C-type natriuretic peptide analogue Vosolitide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456254-A | Synthesis method of C-type natriuretic peptide analogue Vosolitide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-07-26 | — | — | US | disclosed |
| WO-2017008033-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Reasearch & Business Foundation Sungkyunkwan University (KR) | 2017-01-12 | — | — | WO | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032060-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032077-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| US-4432971-A | HYPOTENSIVE AGENTS AND ANGIOTENSIN INHIBITION | E. R. SQUIBB & SONS, INC. (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0071544-A1 | Phosphonamidate compounds | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | SI, NOD2, TNF | SMN1; SMN2 2663/4885ALDH1A1 873/4885KMT2A 4521/4885 |
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | SI, NOD2, TNF | SMN1; SMN2 2663/4885ALDH1A1 873/4885KMT2A 4521/4885 |
| US-20230018246-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | NOD2, SI, APC | SMN1; SMN2 3537/4885ALDH1A1 2316/4885KMT2A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.